Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2012

View Archived Issues

Lorvotuzumab mertansine evaluated in patients with solid tumors

Merck KGaA discloses novel agents for cancer

GlaxoSmithKline patents new RIP-2 inhibitors

Daiichi Sankyo divulges new Mdm2/p53 inhibitors

Novel AMPK activators synthesized at GlaxoSmithKline

Japanese researchers disclose new glucokinase activators

Plavix gets Japanese approval for additional indication

Intramuscular injection formulation of Zyprexa approved in Japan

Biotie Therapies describes novel SSAO inhibitors

Suini approved in Japan for type 2 diabetes

Bayer HealthCare joins forces with Evotec on endometriosis

Shionogi and Kotobuki Pharmaceutical sign license agreement for cholesterol absorption inhibitor

Ramucirumab shows activity in non-small cell lung cancer

Progenics Pharmaceuticals begins phase II PSMA-ADC trial in prostate cancer

Dacogen gains approval in the E.U. for acute myeloid leukemia

Results of lenvatinib trials in different kinds of cancer presented

Humira obtains new approval in the U.S.

Novo Nordisk discontinues development of vatreptacog alfa

Subcutaneous Velcade approved in Europe for multiple myeloma

Novo Nordisk's insulin degludec obtains first approval

Antisense Therapeutics provides update on ATL-1102 collaboration

Medicure to develop transdermal formulation of Aggrastat

Apricus Biosciences plans Canadian submission for MycoVa

FDA approval sought for tivozanib

A.P. Pharma resubmits APF-530 NDA

European approval for Seebri Breezhaler

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...